Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

被引:318
作者
Hochholzer, W [1 ]
Trenk, D [1 ]
Frundi, D [1 ]
Blanke, P [1 ]
Fischer, B [1 ]
Andris, K [1 ]
Bestehorn, HP [1 ]
Büttner, HJ [1 ]
Neumann, FJ [1 ]
机构
[1] Herz Zentrum Bad Krozingen, D-79189 Bad Krozingen, Germany
关键词
stents; coronary disease; platelets; drugs;
D O I
10.1161/01.CIR.0000160869.75810.98
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Pretreatment with clopidogrel can reduce the risks associated with percutaneous coronary intervention ( PCI). To shorten the time for clopidogrel to become effective, a 600- mg loading dose has been used. We sought to validate this regimen in a large cohort and investigated the time dependence of the antiplatelet effect of 600 mg of clopidogrel. Methods and Results - Our study included 1001 patients who were scheduled for cardiac catheterization as potential candidates for PCI. We obtained blood samples before administration of 600 mg of clopidogrel and at the time of catheterization, which varied according to logistic needs. We assessed platelet aggregation by optical aggregometry and surface expression of P- selectin and activated glycoprotein IIb/ IIIa by flow cytometry. Platelet aggregation induced by 5 mu mol/ L ADP was 51 +/- 14% when catheterization was performed at < 1 hour, 41 +/- 14% at 1 to < 2 hours, 37 +/- 15% at 2 to < 4 hours, 36 +/- 13% at 4 to < 6 hours, and 35 +/- 14% at >= 6 hours after clopidogrel administration. After 2 hours ( n = 718), the level of platelet aggregation and the surface expression of P- selectin and activated glycoprotein IIb/ IIIa did not change significantly with time after clopidogrel ( P > 0.24 by univariate or multivariate regression). Comedication with CYP3A4 metabolized statins did not significantly affect platelet aggregation after clopidogrel ( P = 0.62). Among the 428 patients undergoing PCI, the 30- day composite rate of major adverse cardiac events was 1.9%, with no significant difference between patients undergoing PCI within 2 hours after clopidogrel loading and those undergoing PCI at a later time point. Conclusions - After loading with 600 mg of clopidogrel, the full antiplatelet effect of the drug is achieved after 2 hours. Statins do not interfere with the level of platelet inhibition after this dose.
引用
收藏
页码:2560 / 2564
页数:5
相关论文
共 12 条
[1]   High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability [J].
Angiolillo, DJ ;
Fernández-Ortiz, A ;
Bernardo, E ;
Ramírez, C ;
Sabaté, M ;
Bañuelos, C ;
Hernández-Antolín, R ;
Escaned, J ;
Moreno, R ;
Alfonso, F ;
Macaya, C .
EUROPEAN HEART JOURNAL, 2004, 25 (21) :1903-1910
[2]   Antiplatlet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to cononary artery stenting [J].
Gorchakova, O ;
von Beckerath, N ;
Gawaz, M ;
Mocz, A ;
Joost, A ;
Schömig, A ;
Kastrati, A .
EUROPEAN HEART JOURNAL, 2004, 25 (21) :1898-1902
[3]   Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization [J].
Kandzari, DE ;
Berger, PB ;
Kastrati, A ;
Steinhubl, SR ;
Mehilli, J ;
Dotzer, F ;
ten Berg, JM ;
Neumann, FJ ;
Bollwein, H ;
Dirschinger, J ;
Schömig, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) :2133-2136
[4]   A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel [J].
Kastrati, A ;
Mehilli, J ;
Schühlen, H ;
Dirschinger, J ;
Dotzer, F ;
ten Berg, JM ;
Neumann, F ;
Bollwein, H ;
Volmer, C ;
Gawaz, M ;
Berger, PB ;
Schomig, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (03) :232-238
[5]   Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction [J].
Lau, WC ;
Waskell, LA ;
Watkins, PB ;
Neer, CJ ;
Horowitz, K ;
Hopp, AS ;
Tait, AR ;
Carville, DGM ;
Guyer, KE ;
Bates, ER .
CIRCULATION, 2003, 107 (01) :32-37
[6]   Clopidogrel is an inducer and a potent reversible inhibitor of cytochrome P450 3A4 in vitro [J].
Lau, WC ;
Rae, JM ;
Hollenberg, PF ;
Bates, ER .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) :493A-493A
[7]   Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study [J].
Mehta, SR ;
Yusuf, S ;
Peters, RJG ;
Bertrand, ME ;
Lewis, BS ;
Natarajan, MK ;
Maimberg, K ;
Rupprecht, HJ ;
Zhao, F ;
Chrolavicius, S ;
Copland, I ;
Fox, KAA .
LANCET, 2001, 358 (9281) :527-533
[8]   Effects of statins on platelet inhibition by a high loading dose of clopidogrel [J].
Müller, I ;
Besta, F ;
Schulz, C ;
Li, ZY ;
Massberg, S ;
Gawaz, M .
CIRCULATION, 2003, 108 (18) :2195-2197
[9]   Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement [J].
Müller, I ;
Seyfarth, M ;
Rüdiger, S ;
Wolf, B ;
Pogatsa-Murray, G ;
Schömig, A ;
Gawaz, M .
HEART, 2001, 85 (01) :92-93
[10]   Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting [J].
Neumann, FJ ;
Hochholzer, W ;
Pogatsa-Murray, G ;
Schömig, A ;
Gawaz, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) :1323-1328